Stocktoria
Bio Green Med Solution, Inc. BGMS
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1996-01-01
Bio Green Med Solution, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $747,000 | $43,000 | $420,000 | $0 | $0 | $0 | — | $150,000 | $0 | $843,000 |
| R&D expense | $848,000 | $6.7M | $19.2M | $20.3M | $15.5M | $4.8M | $4.7M | $4.3M | $4.2M | $9.5M |
| SG&A expense | — | $5.4M | $6.7M | $7.4M | $7.5M | $5.9M | $5.0M | $5.4M | $5.3M | $5.5M |
| Operating income | -$8.4M | -$12.0M | -$25.5M | -$27.7M | -$22.9M | -$10.6M | -$9.7M | -$9.5M | -$9.5M | -$14.2M |
| Income tax | $7,000 | -$782,000 | -$3.0M | -$4.7M | -$3.8M | -$1.2M | -$1.3M | -$1.3M | -$993,000 | -$2.0M |
| Net income | -$3.0M | -$11.2M | -$22.6M | -$21.2M | -$18.9M | -$8.4M | -$7.8M | -$7.3M | -$7.5M | -$11.8M |
| EPS (diluted) | $-6.45 | $-502.46 | $-26.75 | $-27.24 | $-2.14 | $-3.42 | — | — | — | — |
| Operating cash flow | -$4.8M | -$8.0M | -$16.1M | -$20.8M | -$18.5M | -$7.9M | -$9.4M | -$6.7M | -$7.5M | -$10.1M |
| Free cash flow | — | — | -$16.1M | -$20.8M | -$18.6M | -$8.0M | -$9.5M | -$6.7M | -$7.5M | -$10.1M |
| Cash & equivalents | $3.5M | $3.1M | $3.4M | $18.3M | $36.6M | $33.4M | $11.9M | $17.5M | $23.9M | $16.5M |
| Inventory | $1.4M | — | — | — | — | — | — | — | — | — |
| Total assets | $8.2M | $4.1M | $8.8M | $28.1M | $42.6M | $36.8M | $15.3M | $19.8M | $26.0M | $19.7M |
| Total liabilities | $1.3M | $6.3M | $8.2M | $7.6M | $5.3M | $3.5M | $3.6M | $4.6M | $4.2M | $5.4M |
| Shareholders' equity | $6.8M | -$2.2M | $607,000 | $15.9M | $37.7M | $33.3M | $11.7M | $15.3M | $21.8M | $14.3M |
Growth · year-over-year · Revenue CAGR -1.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +1637.2% | -89.8% | — | — | — | — | — | — | -100.0% | -56.6% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.